GLP-1R agonists ameliorate both diabetes and obesity, decrease cardiovascular events, stroke and nephropathy in clinical trials8,9 and ameliorate dementia and stroke in preclinical studies51. This evidence concerns the gene GLP1R and obesity disorder.